Prolyl Oligopeptidase Inhibitor Shows Promise in Reducing Tau Pathology.
Alzheimer's disease (AD) remains a mystery, with no highly effective treatments available. However, research into Treg therapy, which promotes regulatory T-cell function, has shown promise in slowing AD progression by down-regulating inflammation and fighting off amyloid protein build-up. Coya Therapeutics is a clinical-stage biotechnology company leading the field in developing Treg therapies, with COYA 301 aiming to reduce neuroinflammation by supporting the development, expansion, and activity of Treg cells in the brain. The company will release clinical data in mid-May illustrating the preliminary efficacy of COYA 301 and biomarkers for eight patients with AD.